Tonix Pharmaceuticals To Present Clinical Data At The 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress

NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present efficacy and safety results of TNX-102 SL* for the treatment of military-related PTSD in a poster at the 2016 NEI Psychopharmacology Congress being held November 3-6, 2016 in Colorado Springs, CO.

Gregory Sullivan, M.D., chief medical officer of Tonix, will present the poster, titled, "The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD" (Poster No.: 186).

Tonix recently held a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) based on positive data from its 12-week randomized, double-blind, placebo-controlled Phase 2 AtEase clinical trial.  Tonix intends to commence a 12-week Phase 3 study evaluating TNX-102 SL, 5.6 mg, in military-related PTSD in the first quarter of 2017.
Event:   2016 NEI Psychopharmacology Congress
Title:   The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD
Date:   Friday, November 4, 2016
Time:   6:00pm-7:30pm (MDT)
Location:     Exhibit Hall, Poster No. 186, The Broadmoor, Colorado Springs, CO
     

*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an Investigational New Drug and has not been approved for any indication.

If you liked this article you might like

Mirati Skyrockets On Positive Data - Biotech Movers

5 Stocks Poised for Major Breakouts

Can You Catch These 6 Stocks Under $10 on Their Way Up?

6 Stocks Under $10 Making Big Moves Higher

Trade These 5 Breakout Stocks for Big Gains